Skip to content

Who We Are
- Leadership
- Our Culture
Careers
Contact Us

Our Science
Our Medicines
Medical Professionals
- Overview
- HCP Resources
Patients & Advocacy
Investors & Media

Our Science
Our Medicines
Medical Professionals
- Overview
- HCP Resources
Patients & Advocacy
Investors & Media
Who We Are
- Leadership
- Our Culture
Careers
Contact

Phase I study of the combination of the dual RAF/MEK inhibitor Avutometinib and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Phase I study of the combination of the dual RAF/MEK inhibitor Avutometinib and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Phase I Study

Terms of Use
Compliance & Ethics
Copyright Statement
Privacy Policy
Contact
Sitemap

Twitter
Linkedin

© 2025 Verastem, Inc. All Rights Reserved.

This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Privacy Policy.